Roger Jeffs, the chief executive officer of Liquidia Corp (NASDAQ:LQDA), disposed of 25,000 shares of common stock on April 9, 2026, generating total proceeds of $1,002,887. The sale was executed at a weighted average price of $40.1155, with individual trade prices spanning $40.00 to $40.33.
The transaction was carried out under a pre-established Rule 10b5-1 trading plan that the company says was adopted on November 5, 2025. The sale comes against the backdrop of a strong 12-month performance for Liquidia shares - a 188% return over the past year - although current quotes sit at $38.79, which is modestly below the weighted average price Jeffs achieved with this sale.
After completing the sale, Jeffs retains direct ownership of 1,142,176 shares of Liquidia stock, a figure that includes unvested restricted stock units. He additionally holds 46,595 shares indirectly through the Roger A. Jeffs Living Trust and has further indirect holdings via Serendipity BioPharma LLC.
On the operating front, Liquidia reported robust fourth-quarter 2025 revenue for its commercial product Yutrepia, with sales of $90.1 million - a 74% increase from the prior quarter. Despite the top-line strength, the company posted an earnings per share result that fell short of expectations, yielding a mixed set of financial signals for the quarter.
Analyst reactions have generally been positive even with the EPS miss. H.C. Wainwright raised its price target to $55 and kept a Buy rating, citing Liquidia's movement toward profitability. BTIG lifted its target to $50, while BofA Securities reiterated a Buy rating with a $44 target, pointing to the company's competitive position in prostacyclin therapies. Raymond James maintained a Strong Buy stance and set a $47 target, observing that Yutrepia's initial launch metrics compare favorably to the early performance of Tyvaso DPI. Management has provided revenue guidance that exceeds $1 billion for 2027.
Collectively, the insider sale, recent quarterly results and the analysts' responses create a nuanced picture for Liquidia. The stock's recent historic gains and the company's revenue trajectory for Yutrepia are positive indicators, even as the EPS miss and the CEO's sale under a standing plan introduce elements for investors to weigh.
Summary
Liquidia's CEO sold 25,000 shares via a Rule 10b5-1 plan on April 9, 2026, netting roughly $1.003 million. The company reported strong Yutrepia revenue in Q4 2025 but recorded an EPS shortfall. Several analysts raised price targets or reiterated Buy ratings, and management expects revenue above $1 billion in 2027.